Harmony Biosciences: CEO to retire; COO promoted

What happened

• Harmony Biosciences Holdings, Inc. announced that Jeffrey M. Dayno, M.D., will retire as the company’s president and chief executive officer and will step down as a Class I director effective Dec 31, 2026, at 11:59 p.m. Eastern Time, and will serve as a non-executive advisor through 2027.
• The company announced that Peter Anastasiou, the current chief operating officer, has been appointed by the board to serve as president and chief executive officer effective Jan 1, 2027, at 12:00 a.m. Eastern Time, and appointed as a Class I director with a term expiring at the company’s 2027 annual meeting of stockholders.

Key details

• Jeffrey M. Dayno, M.D.: retirement and resignation from the board effective Dec 31, 2026 at 11:59 p.m. Eastern Time; will serve as non-executive advisor through 2027.
• Peter Anastasiou, age 55: COO since Apr 2026; appointed president and CEO effective Jan 1, 2027 at 12:00 a.m. Eastern Time and appointed as a Class I director through the 2027 annual meeting.
• Anastasiou background: CEO and board member of Capsida Biotherapeutics Jan 2022 to Oct 2025; roles at Lundbeck Nov 2009 to Dec 2021; B.A. in economics and management from Albion College; M.B.A. from Kelley School of Business, Indiana University.
• The filing states there are no arrangements or understandings by which Anastasiou was selected, no family relationships with any director or executive officer, no transactions required to be reported under Item 404(a) of Regulation S-K, and he will not receive additional compensation for his service as a director.

Why it may matter

• The report was made under Item 5.02 (departure of directors or certain officers; election of directors) and Item 7.01 (regulation FD disclosure), which cover the retirement of an executive and the appointment of a successor and the company’s public disclosure of the transition. This filing does not show why the insider traded or why the company acted.